BioGaia Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Theresa Agnew

Chief Executive Officer (CEO)

SEK 6.8m

Compensación total

Porcentaje del salario del CEO	19.4%
Permanencia del CEO	1.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Oct 29

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Apr 25

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 09

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Mar 26

BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90

Mar 09

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Feb 24

Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?

Jul 24

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

Apr 02

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 21

Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues

Feb 09

BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 07

Some Shareholders May find It Hard To Increase BioGaia AB (publ)'s (STO:BIOG B) CEO Compensation This Year

Apr 29

Key Things To Consider Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend

Mar 25

The BioGaia (STO:BIOG B) Share Price Is Up 90% And Shareholders Are Holding On

Mar 04

CEO & President Isabelle Valerie Ducellier Just Bought 8.2% More Shares In BioGaia AB (publ) (STO:BIOG B)

Feb 11

Is BioGaia AB (publ)'s (STO:BIOG B) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 26

What Type Of Shareholders Own The Most Number of BioGaia AB (publ) (STO:BIOG B) Shares?

Jan 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Theresa Agnew en comparación con los beneficios de BioGaia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	SEK 337m
Jun 30 2024	n/a	n/a	SEK 402m
Mar 31 2024	n/a	n/a	SEK 371m
Dec 31 2023	SEK 7m	SEK 1m	SEK 365m

Compensación vs. Mercado: La compensación total ($USD611.22K) de Theresa está en línea con el promedio de empresas de tamaño similar en el mercado Swedish ($USD733.44K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Theresa con los resultados de la empresa.

CEO

Theresa Agnew (58 yo)

1.3yrs

Permanencia

SEK 6,750,250

Compensación

Ms. Theresa P. Agnew serves as President of BioGaia AB (publ) since September 2023 and serves as its Chief Executive Officer since 25 September 2023. She is a global business leader with consumer healthcar...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Rothschild	Founder & Chairman	6.7yrs	SEK 1.33m	sin datos
Theresa Agnew	CEO & President	1.3yrs	SEK 6.75m	sin datos
Alexander Kotsinas	Executive VP & CFO	5.1yrs	SEK 3.07m	0.0030% SEK 331.1k
Ludvig Milesson	Chief Operating Officer	1.7yrs	sin datos	0.0012% SEK 138.2k
Gianfranco Grompone	Chief Scientific Officer and VP of Research & Development	4.9yrs	sin datos	sin datos
Caroline Mofors	Chief Legal Officer	1.9yrs	sin datos	sin datos
Linda Hagglund	Vice President of Marketing	3.6yrs	sin datos	0.0012% SEK 131.5k
Angelika Kjelldorff	Chief HR Officer	5.9yrs	sin datos	0.00049% SEK 54.6k
Sebastian Heimfors	VP & Chief Commercial Officer	2.8yrs	sin datos	sin datos
Jonathan Gromark	Sustainability Manager	no data	sin datos	sin datos
Keitaro Nomura	MD & President of BioGaia Japan Inc.	no data	sin datos	sin datos

3.6yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BIOG B se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Rothschild	Founder & Chairman	6.7yrs	SEK 1.33m	sin datos
David E. Dangoor	Independent Deputy Board Chairman	21.9yrs	SEK 590.00k	1.73% SEK 192.8m
Vesa Koskinen	Director	1.6yrs	SEK 275.00k	sin datos
Barbro Friden	Director	1.6yrs	SEK 275.00k	0.00049% SEK 54.6k
Anthon Jahreskog	Independent Director	9.6yrs	SEK 405.00k	0.0040% SEK 444.8k
Vanessa Rothschild	Director	4.6yrs	SEK 275.00k	0.00016% SEK 17.8k
Benedicte Flambard	Director	2.6yrs	SEK 275.00k	sin datos
Outi Armstrong	Director	1.6yrs	SEK 275.00k	sin datos

3.6yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de BIOG B se considera experimentada (3.6 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2024/12/23 17:48
Precio de las acciones al final del día	2024/12/23 00:00
Beneficios	2024/09/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

BioGaia AB (publ) está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Christopher Uhde	ABG Sundal Collier Sponsored
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Mattias Häggblom	Danske Bank

BioGaia Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Vice President of Marketing exercised options to buy kr579k worth of stock.

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Recent updates

BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTION

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)

BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025

Price target increased by 7.1% to kr150

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Vice President of Marketing exercised options to buy kr579k worth of stock.

Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)

BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2023 earnings: EPS and revenues exceed analyst expectations

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Price target increased by 22% to kr140

BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biogaia AB (Publ) Proposes an Extra Dividend

Here's Why We Think BioGaia (STO:BIOG B) Might Deserve Your Attention Today

BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024

Third quarter 2023 earnings released

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Second quarter 2023 earnings released

BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults

Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?

Less than half of directors are independent

First quarter 2023 earnings released

BioGaia AB (Publ) Approves Dividend for 2022

Upcoming dividend of kr2.90 per share at 2.8% yield

A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

Full year 2022 earnings: EPS exceeds analyst expectations

Independent Director recently bought kr51k worth of stock

Price target increased by 9.1% to kr120

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

BioGaia AB (publ) Proposes Ordinary Dividend

Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?

Price target decreased to kr102

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?

Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022

Price target increased to kr620

BioGaia AB (publ) Approves Extra Dividend

First quarter 2022 earnings: Revenues exceed analyst expectations

Upcoming dividend of kr14.92 per share

Price target increased to kr570

BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022

BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

Full year 2021 earnings: EPS and revenues exceed analyst expectations

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Consensus revenue estimates increase by 10%

Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues

BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Biogaia AB (Publ) Proposes Ordinary Dividend

BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis

BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)